The tumour suppressor p53 is the most frequently mutated gene in human cancer, with more
than half of all human tumours carrying mutations in this particular gene. Intense efforts to …

Peptide-based drug discovery has experienced a significant upturn within the past decade
since the introduction of chemical modifications and unnatural amino acids has allowed for …

Mutations in the TP53 gene are a feature of 50% of all reported cancer cases. In the other
50% of cases, the TP53 gene itself is not mutated but the p53 pathway is often partially …

High-diversity genetically-encoded combinatorial libraries (108− 1013 members) are a rich
source of peptide-based binding molecules, identified by affinity selection. Synthetic libraries …

The overexpression of Hdm2 and HdmX is a common mechanism used by many tumor cells
to inactive the p53 tumor suppressor pathway promoting cell survival. Targeting Hdm2 and …

Understanding and control of structures and rates involved in protein ligand binding are
essential for drug design. Unfortunately, atomistic molecular dynamics (MD) simulations …

By using a phage display derived peptide as an initial template, compounds have been
developed that are highly specific against Mdm2/Mdm4. These compounds exhibit greater …

In recent years, protein science has been revolutionized by the discovery of intrinsically
disordered proteins (IDPs). In contrast to the classical paradigm that a given protein …

The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor
suppressor protein p53, conferring tumor development and survival. Antagonists targeting …

Rationale: Although stapled peptides offer a powerful solution to overcome the susceptibility
of linear peptides to proteolytic degradation and improve their ability to cross membranes …